Lv12
78 积分 2023-12-19 加入
Targeting EZH2 for cancer therapy: From current progress to novel strategies
1天前
待确认
Roles of the EZH2 histone methyltransferase in cancer epigenetics
1天前
已完结
Focus on the classical and non-classical functions of EZH2: Guide the development of inhibitors and degraders
1天前
已完结
8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)
22天前
已完结
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
23天前
已完结
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
24天前
已完结
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
24天前
已完结
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
24天前
已完结
成人原发免疫性血小板减少症诊断与治疗中国指南（2020年版）解读
25天前
已完结
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
1个月前
已完结
皖公网安备34019202002308
